Adheris Health Limited · ASX:AHE
Adheris Health — MedAdvisor — 1H FY25 Earnings Presentation
25 slides from Adheris Health's earnings presentation, Feb 27, 2025
Slide 1: 1H FY25 Investor Update: Reshaping MedAdvisor for Long Term Value Creation
For personal use only 1H FY25 Investor Update Reshaping MedAdvisor for Long Term Value Creation 28 February 2025
Slide 2: Important notice and disclaimer
Important notice and disclaimer For personal use only This presentation provides general information about completeness of the information or for any of the opinions regulatory requirements. This presentation does not constitute MedAdvisor Solutions which is current at the date this contained herein
Slide 3: Agenda
Agenda For personal use only 1 1H FY25 Overview 2 Financial and Operational Update 3 Industry Drivers 4 2H FY25 Outlook Rick Ratliff Ancila Desai CEO & Managing Director CFO & Company Secretary 3 1H FY25 Investor Update: Reshaping MedAdvisor @ 2025 MedAdvisor Solutions. All rights reserved.
Slide 4: 1H FY25 overview
For personal use only 1H FY25 overview 4 1H FY25 Investor Update: Reshaping MedAdvisor @ 2025 MedAdvisor Solutions. All rights reserved.
Slide 5: Investor overview
Investor overview For personal use only MedAdvisor Solutions is a global leader of innovative, pharmacy-driven patient engagement solutions that provide individualised patient experiences to help remove barriers to care • Delivered IH FY25 group revenue of • ANZ business continues to grow with $57.1
Slide 6: Financial and operational update
For personal use only Financial and operational update 6 1H FY25 Investor Update: Reshaping MedAdvisor @ 2025 MedAdvisor Solutions. All rights reserved.
Slide 7: 1H FY25 group financial highlights
1H FY25 group financial highlights For personal use only Financial category (AUD) 1H FY25 1H FY24 Change Revenue impacted by lower- than-expected vaccination rates, Revenue $57.1m $75.5m -24.4% leading to delays in pharma- spend Gross Profit $35.0m $43.4m -19.4% Gross profit impacted by decline in r
Slide 8: EBITDA remains positive
EBITDA remains positive For personal use only EBITDA (adjusted) Revenue and margin impact: Decline due to lower- than-expected vaccination rates, leading to delays in pharma-spend, impact of marketing incentives as a discount ($0.4m) and cloud related expenses ($0.5m). $11.9m $5.9m Marketing & commu
Slide 9: Cash position of $12.4m
Cash position of $12.4m For personal use only Cash Cash flow reflects strategic cost controls and investment priorities. Receipts from customers and payments to suppliers: Lower receipts due to decline is revenue offset by timing of supplier payments. In addition, $1m attributable to one additional
Slide 10: US: 1H FY25 highlights
US: 1H FY25 highlights For personal use only Market shifts impact first half results Decrease in 1H revenue from $64.5M 1H FY24 Revenue by channel 1H FY25 revenue by category $41.3m Other 4% $45.7M Specialty 8% Down by 29.1% YoY Vaccine Gen Meds 51% 37% Gross profit $17.0m $16.1m $16.0m $25.6M $12.0
Slide 11: US: Revenue analysis by category
US: Revenue analysis by category For personal use only Market shifts impact revenue across categories 1H FY25 general medications revenue 1H FY25 vaccine revenue 1H FY25 specialty revenue Gastrointestinal 1% Laxatives 1% Migraine Products 1% HPV 1% Gout 1% Arrhythmia 1% Anti-Inflammatory 1% Dietary
Slide 12: Weekly vaccine volume across MDR network
For personal use only 12 Weekly vaccine volume across MDR network 1,000,000 800,000 400,000 1,200,000 0 600,000 200,000 1,400,000 Trend Action 10/20/2020 - 10/26/2020 10/27/2020 - 11/2/2020 11/3/2020 - 11/9/2020 11/10/2020 - 11/16/2020 11/17/2020 - 11/23/2020 11/24/2020 - 11/30/2020 12/1/2020 - 12/7
Slide 13: US case study: Advancing solutions for specialty medications
US case study: Advancing solutions for specialty medications For personal use only In pharmacy education drives awareness and specialist visits: addressing gaps in severe asthma The Asthma Biologic in Pharmacy Program used pharmacy visits to educate severe asthma patients about advanced treatments,
Slide 14: ANZ: 1H FY25 highlights
ANZ: 1H FY25 highlights For personal use only Revenue growth supported by transactions and health programs Increase in 1H revenue from $11.1M 1H FY24 Key initiatives $11.4M Up by 2.7% YoY 90% Customers migrated to cloud, as part of Transformation 360⁰ for anytime/anywhere access, improving performan
Slide 15: AU Case Study: Growing opportunity for pharmacist led programs
AU Case Study: Growing opportunity for pharmacist led programs For personal use only Pharma sponsored patient program delivers significant revenue Services delivered by pharmacists in pharmacy offer a key patient engagement channel for pharmaceutical companies in Australia. Following the launch of a
Slide 16: Transformation update: On time and on budget
Transformation 360 update: On time and on budget o For personal use only A self-funded initiative designed to enhance operational efficiency, agility, and Initiative currently Restructuring to achieve All programs on target US platform competitiveness by leveraging estimated to be around annualised
Slide 17: THRiV: Next-gen patient engagement platform
THRiV: Next-gen patient engagement platform Psychographic data segmentation Personalised interventions Patient centric engagement For personal use only Integrated, identified Deliver the “Next Best Actions” at an individual level Effective, tailored patient level datasets to guide patient engagement
Slide 18: Industry drivers
For personal use only Industry drivers 18 1H FY25 Investor Update: Reshaping MedAdvisor @ 2025 MedAdvisor Solutions. All rights reserved.
Slide 19: Evolving market trends reshaping pharmacy & pharma landscape
Evolving market trends reshaping pharmacy & pharma landscape For personal use only MedAdvisor is leveraged to capitalize on these trends United States Pharma industry: DTC models Pharmacy sector: Pharmacy Consumer trends: Growing Governmental influence: New reshaping patient engagement (e.g., chains
Slide 20: US: Leveraging Transformation 360 to accelerate reshaping US business
US: Leveraging Transformation 360 to o TRANSFORMATION Transforming our platform, accelerate reshaping US business business processes, and go- For personal use only to-market strategy to align with market shifts Focus on the customer Operational excellence Collaboration • Adjust go-to-market (GTM) st
Slide 21: AU: Leveraging Transformation 360 to accelerate market alignment
AU: Leveraging Transformation 360o to TRANSFORMATION Expanding pharmacist-led accelerate market alignment services, enhancing digital For personal use only engagement, and leveraging AI to improve medication management Focus on the customer Operational excellence Collaboration • Utilise Pharmacy Adv
Slide 22: AU: Regulatory tailwinds create catalyst for scope of practice growth
AU: Regulatory tailwinds create catalyst for scope of practice growth For personal use only Australian women’s health initiative highlights pharmacy’s role in access to care Projected Scope of Practice Revenue Growth Projected Cases by Category (FY29) Dermatology Travel Health 1% 2% Acute and Chroni
Slide 23: 2H FY25 outlook
For personal use only 2H FY25 outlook 23 1H FY25 Investor Update: Reshaping MedAdvisor @ 2025 MedAdvisor Solutions. All rights reserved.
Slide 24: 2H FY25 outlook
2H FY25 outlook For personal use only Strategic Growth Pipeline by Category ($) US business redesign Cost optimization ANZ US Other 6%% Other 8% • Optimize sales cycle and • Review additional Meds Info 10% drive pipeline conversion opportunities for opex SaaS Revenue Specialty Gen Med 54% • Drive gr
Slide 25: Thank you
For personal use only Thank you medadvisorsolutions.com 25 1H FY25 Investor Update: Reshaping MedAdvisor @ 2025 MedAdvisor Solutions. All rights reserved.